Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL SUSPENSIONGeneric

LAMIVUDINE; ZIDOVUDINE

LAMIVUDINE; ZIDOVUDINE

Standard Dose
30MG; 60MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE; ZIDOVUDINE is listed in Drugs@FDA under application 204914 (NDA).

Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE Form and strength TABLET; ORAL SUSPENSION - 30MG; 60MG Sponsor MYLAN LABS Submission history Latest submission status date: 2015-05-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE; ZIDOVUDINE is listed in Drugs@FDA under application 204914 (NDA). Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE Form and strength TABLET; ORAL SUSPENSION - 30MG; 60MG Sponsor MYLAN LABS Submission history Latest submission status date: 2015-05-14 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: None (Tentative Approval)

Interaction Notes

  • No interaction notes stored yet.